FDA
-
-
-
-
-
-
-
Novartis CEO defends $12 billion deal for Avidity as 'appropriate risk to take'
-
-
-
-
-
-
-
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44
-
-
-
-
-
-
-
Goldman Sachs Resumes Avidity Biosciences (RNA) at Buy
-
-
-
-
-
-
-
Avidity Biosciences (RNA) PT Lowered to $68 at H.C. Wainwright
-
-
-
-
-
-
-
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duc
-
-
-
-
-
-
-
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
-
-
-
-
-
-
-
Avidity Biosciences Inc. (RNA) Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran
-
322,996 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

